47 terminated. 47 Phase 2, 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 47 | Terminated 47 |
| Phase 1 | 10 | Terminated 10 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis RVU120, Ruxolitinib - Myelofibrosis | Phase 2 | Terminated | Ryvu Therapeutics SA | 36 | 2024-09-19 | 2026-09-16 |
| A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) TQ05105 tablets, TQB3909 tablets - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 21 | 2024-05-13 | 2026-01-05 |
| Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis NS-018, Best Available Therapy - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Terminated | NS Pharma, Inc. | 7 | 2023-01-31 | 2025-05-23 |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Jaktinib, azacitidine - Myelodysplastic Syndromes, Myeloproliferative Neoplasms | Phase 1 / Phase 2 | Terminated | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 1 | 2021-09-30 | 2022-12-01 |
| Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia Fostamatinib, Ruxolitinib - Myelofibrosis, Thrombocytopenia | Phase 2 | Terminated | Washington University School of Medicine | 3 | 2021-05-03 | 2023-12-15 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib itacitinib - Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans) | Phase 2 | Terminated | Incyte Corporation | 18 | 2021-03-10 | 2026-06-26 |
| Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Ruxolitinib, Siremadlin, Crizanlizumab - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 45 | 2019-09-26 | 2025-08-07 |
| Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors Selinexor - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Terminated | University of Utah | 17 | 2019-05-10 | 2026-10-26 |
| AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis Combination AZD1775 with AraC, AZD1775 only - Myelofibroses, Acute Myeloid Leukemia | Phase 2 | Terminated | NYU Langone Health | 6 | 2019-05-08 | 2020-06-02 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 12 | 2019-02-20 | 2026-04-24 |
| Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Busulfan, Cyclophosphamide, Fludarabine - Anemia, ASXL1 Gene Mutation | Phase 2 | Terminated | University of Utah | 6 | 2018-03-30 | 2022-05-05 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission | Phase 2 | Terminated | Roswell Park Cancer Institute | 31 | 2017-12-07 | 2025-07-04 |
| Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Rigosertib, Questionnaire - Leukemia, Myelofibrosis | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2017-08-16 | 2020-08-07 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Platelet Transfusion - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 4 | 2017-06-09 | 2019-10-21 |
| A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Parsaclisib, Ruxolitinib - MPN (Myeloproliferative Neoplasms) | Phase 2 | Terminated | Incyte Corporation | 74 | 2017-02-08 | 2024-05-01 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Thymoglobulin, Bortezomib, Tacrolimus - Acute Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Terminated | Emory University | 5 | 2016-09-01 | 2018-04-30 |
| Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies INCB057643, Gemcitabine, Paclitaxel - Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 137 | 2016-05-18 | 2025-10-21 |
| An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies INCB059872, all-trans retinoic acid (ATRA), azacitidine - Solid Tumors and Hematologic Malignancy | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 116 | 2016-05-05 | 2025-11-04 |
| Study of INCB053914 in Subjects With Advanced Malignancies INCB053914, I-DAC (Intermediate dose cytarabine), Azacitidine - Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 97 | 2015-12-29 | 2021-12-08 |
| P1101 in Treating Patients With Myelofibrosis Laboratory Biomarker Analysis, Quality-of-Life Assessment, Ropeginterferon Alfa-2B - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Terminated | Mayo Clinic | 11 | 2015-08-12 | 2025-10-27 |
Showing 20 of 47. Sign in to see all of them.
Myeloproliferative Disorders (21) · Myelodysplastic Syndromes (19) · Leukemia, Myeloid, Acute (17) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Multiple Myeloma (14) · Leukemia (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Lymphoma (11) · Lymphoma, Large B-Cell, Diffuse (11) · Polycythemia Vera (11) · Leukemia, Myelomonocytic, Chronic (9) · Lymphoma, Follicular (9) · Lymphoma, Mantle-Cell (9) · Lymphoma, Non-Hodgkin (9)
Bone Marrow Diseases (47) · Hemic and Lymphatic Diseases (47) · Hematologic Diseases (45) · Neoplasms (30) · Myeloproliferative Disorders (26) · Neoplasms by Histologic Type (25) · Hemorrhagic Disorders (21) · Immune System Diseases (21) · Immunoproliferative Disorders (20) · Leukemia, Myeloid (20) · Pathological Conditions, Signs and Symptoms (20) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (18) · Neoplasms by Site (18) · Pathologic Processes (18)
Antilymphocyte Serum (9) · ruxolitinib (9) · Cyclophosphamide (7) · fludarabine phosphate (7) · Azacitidine (5) · Cyclosporine (5) · Tacrolimus (5) · Busulfan (4) · Methylprednisolone (4) · Peripheral Blood Stem Cell Transplantation (4) · Stem Cell Transplantation (4) · Cord Blood Stem Cell Transplantation (3) · Methotrexate (3) · Mycophenolic Acid (3) · Radiotherapy (3)
Incyte Corporation (6) · H. Lee Moffitt Cancer Center and Research Institute (3) · M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · Novartis Pharmaceuticals (3) · Fred Hutchinson Cancer Center (2) · OHSU Knight Cancer Institute (2) · University of Utah (2) · Asana BioSciences (1) · Astex Pharmaceuticals, Inc. (1) · Barbara Ann Karmanos Cancer Institute (1) · Baylor College of Medicine (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · City of Hope Medical Center (1) · Emory University (1)
United States (41) · Italy (5) · Germany (4) · Belgium (3) · Canada (3) · Spain (3) · United Kingdom (3) · China (2) · Netherlands (2) · Poland (2) · Turkey (Türkiye) (2) · Argentina (1) · Australia (1) · Austria (1) · Denmark (1)
Fred Zheng, M.D. (2) · Ruben A. Mesa, MD (2) · Srdan Verstovsek (2) · Steven C. Goldstein, MD (2) · Adam Mead, MD (1) · Albert Assad, MD (1) · Amy Zhou, M.D. (1) · Bipin N. Savani, MD (1) · Catherine Lee, MD (1) · Colleen Delaney, MD (1) · Colleen Delaney, MD, MSC (1) · David Avigan, MD (1) · David Garcia (1) · Edward Ball, M.D. (1)
PMID 31527168, PMID 21874061, PMID 22766223, PMID 23701016, PMID 23812932, PMID 24355079, PMID 30205231, PMID 37290996, PMID 38290135, PMID 40334082
2017 (2), P30CA015083 (2), 2014 (1), 2019 (1), N01CM62202 (1), P01CA108671 (1), P30CA015704 (1), P30CA016058 (1), P30CA016672 (1), P30CA022453 (1), R01CA132197 (1), T32CA009515 (1), U54HL081030 (1)